Asahi Kasei Bioprocess America receiving the Best Technologies Innovation Award at INTERPHEX 2025THESYS® Cleavage & Deprotection (C&D) and Tangential Flow Filtration (TFF) unit GLENVIEW, Ill., April 28, 2025--(BUSINESS WIRE)--Asahi Kasei Bioprocess America, Inc. (AKBA), a leader in advanced filtration and fluid management solutions for the biopharmaceutical industry, has been recognized with the Best Technologies Innovation Award at INTERPHEX 2025. This recognition was for AKBA’s THESYS® Cleavage & Deprotection (C&D) and Tangential Flow Filtration (TFF) unit, a groundbreaking system redefining oligonucleotide manufacturing efficiency. Oligonucleotides (oligos) are short strands of synthetic DNA or RNA crucial in developing advanced therapies, including those for genetic disorders and cancer. AKBA stood out for creating a novel solution for oligo manufacturing that integrates two traditionally separate unit operations, C&D and UF/DF, into a single streamlined system. Combining them into an automated process maximizes efficiency, which is critical for biomanufacturers that want to increase their oligo throughput and scale production. "Asahi Kasei Bioprocess has been a driving force in advancing oligo manufacturing for years, and innovations like this THESYS unit help develop the next generation of therapeutics," said Chris Rombach, President of Asahi Kasei Bioprocess America. "This award validates our commitment to advancing the field and reflects the value we bring to customers through forward-thinking technologies." INTERPHEX is one of the premier events for the pharmaceutical and biotechnology industries and showcases the latest in drug manufacturing innovation. This year’s award highlights technologies that push boundaries and have the potential to change the way pharmaceutical and biotech companies operate. The THESYS C&D/TFF unit eliminates the need for separate equipment, saving valuable lab floor space. It also enables quick, sequential processing before purification. The standard system includes advanced controls, an ergonomic design, and an integrated tank. Learn more about the benefits and cutting-edge features of the award-winning THESYS C&D/TFF unit. About Asahi Kasei Bioprocess The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances worldwide. Built with pride, built with quality, built to exceed expectations. "Built for You." For more information, please visit https://fluidmgmt.ak-bio.com. Story Continues The Purification Business Unit of Asahi Kasei Bioprocess provides a growing range of innovative hollow-fiber purification products that help biotherapeutics manufacturers safely and efficiently produce medicines that patients can trust under the philosophy: "Assurance Beyond Expectation." Beginning in 1989 with the launch of Planova™, the world’s first virus removal filter, our pioneering tradition of supplying exceptionally reliable bioprocess consumables has continued with the launches of several next-generation virus removal filters as well as purification and clarification products. For more information, please visit https://planova.ak-bio.com. About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to sustainable society by providing Care. For more information, visit www.asahi-kasei.com. Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/. View source version on businesswire.com: https://www.businesswire.com/news/home/20250428775853/en/ Contacts North America Contact: Asahi Kasei America Inc. Christian OKeefe [email protected] Europe Contact: Asahi Kasei Europe GmbH Sebastian Schmidt [email protected] View Comments
Asahi Kasei Bioprocess America Wins Best Technologies Innovation Award at INTERPHEX 2025
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...